Volume 51, Issue 49 pp. 12246-12249
Communication

Discovery of Small-Molecule Inhibitors of the TLR1/TLR2 Complex

Dr. Kui Cheng

Dr. Kui Cheng

Department of Chemistry and Biochemistry and the BioFrontiers Institute, University of Colorado at Boulder, Boulder, CO 80309 (USA)

Search for more papers by this author
Dr. Xiaohui Wang

Dr. Xiaohui Wang

Department of Chemistry and Biochemistry and the BioFrontiers Institute, University of Colorado at Boulder, Boulder, CO 80309 (USA)

Search for more papers by this author
Shuting Zhang

Shuting Zhang

Department of Chemistry and Biochemistry and the BioFrontiers Institute, University of Colorado at Boulder, Boulder, CO 80309 (USA)

Search for more papers by this author
Prof. Dr. Hang Yin

Corresponding Author

Prof. Dr. Hang Yin

Department of Chemistry and Biochemistry and the BioFrontiers Institute, University of Colorado at Boulder, Boulder, CO 80309 (USA)

Department of Chemistry and Biochemistry and the BioFrontiers Institute, University of Colorado at Boulder, Boulder, CO 80309 (USA)Search for more papers by this author
First published: 11 September 2012
Citations: 128

We thank the U.S. National Institutes of Health (DA026950, DA025740s and NS067425) for financial support of this work. The sTLR2 DNA plasmid was kindly provided by Dr. Chiaki Nishitani and Dr. Yoshio Kuroki.

Graphical Abstract

An important regulator of innate immunity, the protein complex of Toll-like receptors 1 and 2 (TLR1/TLR2) provides an attractive target for the treatment of various immune disorders. The novel compound CU-CPT22 can compete with the binding of the specific lipoprotein ligand to TLR1/TLR2 (see picture) with high inhibitory activity and specificity. Repression of downstream signaling from TNF-α and IL-1β was also observed.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.